Greg Verdine
About Greg Verdine
Gregory Verdine is the President and CEO of LifeMine Therapeutics, known for coining the phrase 'drugging the undruggable.' He has made significant contributions to DNA repair and epigenetic DNA methylation, and founded multiple biotech companies.
Gregory Verdine: President and CEO
Gregory Verdine holds the positions of President and CEO, and is widely recognized for coining the phrase 'drugging the undruggable.' His leadership has been instrumental in steering various pharmaceutical and biotech companies. As President and CEO, Verdine has successfully guided several organizations through critical phases of development and growth.
Academic and Scientific Contributions
Gregory Verdine is the Erving Professor at Harvard University and Harvard Medical School. His academic work includes seminal contributions to the understanding of DNA repair mechanisms and epigenetic DNA methylation. Verdine's research has had a profound impact on the fields of genomic stability and molecular biology.
Education: Ph.D. in Chemistry from Columbia University
Gregory Verdine earned his Ph.D. in chemistry from Columbia University, following his B.S. in chemistry from St. Joseph’s University. His postdoctoral training was funded by an NIH fellowship, during which he studied molecular biology at MIT and Harvard Medical School. These educational foundations have played a significant role in his subsequent scientific endeavors.
Biotech Entrepreneurship and Company Founding
Gregory Verdine has founded multiple public and private biotech companies, such as Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, Aileron, and Gloucester Pharmaceuticals. Notably, Gloucester Pharmaceuticals was acquired by Celgene. Companies he founded have successfully brought three drugs to market with FDA approval, demonstrating his impactful role in the biotech industry.
Board Memberships and Leadership Roles
Gregory Verdine has served on the board of directors for several companies, including Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals. He has also been instrumental in the formation and financing of Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals, demonstrating robust leadership skills in various executive capacities including President, CEO, and Chief Scientific Officer.